CJC-1295 vs Dulaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Dulaglutide |
|---|---|---|
| Dose Range | 1 mg–2 mg | 750 mcg–4.5 mg |
| Frequency | Less than daily | Less than daily |
| Cycle Length | 8–12 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. |
| Best For |
What They Have in Common
CJC-1295, Dulaglutide are both commonly used for:
Key Differences
Unique to CJC-1295:
Which Has Stronger Evidence?
| Goal | CJC-1295 | Dulaglutide |
|---|---|---|
| Fat Loss | high | high |
Key Studies
CJC-1295
- A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.
Drug testing and analysis, 2019
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Drug testing and analysis, 2019
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Substance use & misuse, 2016
Dulaglutide
- Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
Annals of internal medicine, 2026
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
Nature, 2026
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.
JAMA cardiology, 2026
Ready to Learn More?
Looking for trusted sources?